Thor Medical ASA
Company Profile
Business description
Thor Medical ASA is a Norway-based biopharmaceutical company. The company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. It uses a proprietary production process that does not involve irradiation or nuclear reactors to produce alpha-emitting materials. These materials are used by radiopharmaceutical companies in the development of cancer therapies.
Contact
Drammensveien 167
Oslo0277
NORT: +47 97414000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
18
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
stocks
Investors overlooking ASX share’s potential
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,750.20 | 68.30 | -0.77% |
| CAC 40 | 7,952.55 | 129.72 | -1.61% |
| DAX 40 | 23,950.57 | 505.69 | -2.07% |
| Dow JONES (US) | 49,526.17 | 537.29 | -1.07% |
| FTSE 100 | 10,195.37 | 177.56 | -1.71% |
| HKSE | 25,775.53 | 187.20 | -0.72% |
| NASDAQ | 26,225.14 | 410.08 | -1.54% |
| Nikkei 225 | 60,545.49 | 863.80 | -1.41% |
| NZX 50 Index | 12,880.92 | 84.09 | -0.65% |
| S&P 500 | 7,408.50 | 92.74 | -1.24% |
| S&P/ASX 200 | 8,519.70 | 58.20 | -0.68% |
| SSE Composite Index | 4,121.62 | 13.77 | -0.33% |